


RECEIVED
CENTRAL FAX CENTER
JUN 14 2006

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and
Trademark Office on the date shown below to
Facsimile Telephone Number 571-273-8300- No. pgs. 2

Donna J. Hittle

Type Name of Person Signing Certificate


Signature

14 June 2006
Date

Attorney Docket No. P50438-1C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Blackburn, et al	14 June 2006
Serial No.:	10/681,421	Group Art Unit: 1645
Filed:	October 7, 2003	Examiner: Patricia Ann Duffy
For:	ANTITHROMBOTIC AGENTS	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REPLY TO REQUIREMENT TO
RESTRICT UNDER 35 U.S.C. § 121**

Sir:

This paper is in response to the Restriction Requirement dated 26 May 2006, setting forth a thirty (30) day shortened statutory period for reply. Claims 1-20 are pending in the application. Claims 1-20 are subject to restriction and/or election requirement. As this response is timely filed within the shortened statutory period for response of thirty (30) days, no fee is required. Please charge any additional fees relating to this paper to Deposit Account No. 19-2570.

Restriction to one of the following invention was required under 35 U.S.C. 121:

I. Claims 1-13 and 17-20, drawn to methods of inhibiting thrombosis or reducing the dose of thrombolytic agent by administering a combination of an anti-coagulation factor monoclonal antibody and a thrombolytic agent, classified in class 424, subclass 158.1

II. Claims 14-16, drawn to method of reducing the dose of thrombolytic agent by administering a combination of an undefined anti-coagulation factor agent and a thrombolytic agent, classified in class 514, subclass 2.

In addition applicant was required under 35 U.S.C. 121 to elect a single disclosed species from: Species A-anti-Factor IX/IXa monoclonal antibody; Species B-anti-Factor X/Xa

Application No.: 10/681,421
Group Art Unit: 1645


2

monoclonal antibody; Species C-anti-Factor XI/XIa monoclonal antibody; Species D-anti-Factor VIII/VIIIa monoclonal antibody; Species E-anti-Factor V/Va monoclonal antibody and Species F-anti-thrombin/prothrombin monoclonal antibody for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicants hereby elects Group I (claims 1-13 and 17-20), and elects species A-anti Factor IX/IXa monoclonal antibody.

Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

Respectfully submitted,



William T. Han
Attorney for Applicants
Registration No. 34,344

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5263
Facsimile (610) 270-5090

N:\han\apps\PCase\AP50438-1C2\Restriction Requirement